| { |
| "task_id": "genome_003", |
| "domain": "KEGG_BRITE", |
| "autonomy_type": "ordered table", |
| "oracle_output_cardinality": 8, |
| "instruction": "我在整理一张日本斑块状银屑病系统用药获批顺序表。请按以下顺序处理：先以截至 2024 年底前已在日本获批、用于斑块状银屑病的系统用药为范围，筛出其中作用于 IL‑17/IL‑23 信号轴的活性成分；再排除所有外用药，以及其他作用轴的系统药物。随后，按这些活性成分在日本的首次批准日期从早到晚排序；如同日获批，则按 DRUG_ID 升序排列。最后，请输出一个多行表，每行格式为 <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>。", |
| "start_url": "https://www.kegg.jp/brite/br08301", |
| "output_format": "请输出一个多行表，每行格式为 <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>。", |
| "oracle_answer": "D09967|Secukinumab|L04AC10|IL17A|2014/12/26\nD10061|Brodalumab|L04AC12|IL17RA|2016/7/4\nD10071|Ixekizumab|L04AC13|IL17A|2016/7/4\nD10438|Guselkumab|L04AC16|IL23A|2018/3/23\nD11052|Risankizumab|L04AC18|IL23A|2019/3/26\nD10400|Tildrakizumab|L04AC17|IL23A|2020/6/29\nD11550|Bimekizumab|L04AC21|IL17A/IL17F|2022/1/20\nD11817|Deucravacitinib|L04AF07|TYK2|2022/9/26", |
| "metadata": { |
| "State-Gated Retrieval": [ |
| "只保留截至 2024-12-31 前已在日本获批、用于斑块状银屑病的系统用药中，真正作用于 IL-17/IL-23 信号轴的活性成分。", |
| "候选集合必须覆盖 ligand side、receptor side 和 TYK2 kinase side，而不是只看 interleukin ligand 一侧。", |
| "最终条目按日本首次批准日期升序排列；如同日则按 DRUG_ID 升序。" |
| ], |
| "dependency_type": "Data + Control", |
| "intra_chain": true, |
| "inter_chain": true, |
| "data_dependency": [ |
| "KEGG disease/drug entry points yield the Japan-approved systemic plaque-psoriasis drug cohort through 2024-12-31", |
| "each drug entry yields target branch, ATC, systemic-use validity, and Japan approval date for IL-17/IL-23-axis candidates", |
| "final rows are produced only after ligand-side, receptor-side, and kinase-side candidates are jointly reconciled and re-sorted by Japan approval date" |
| ], |
| "control_dependency": [ |
| "entry-point coverage must include receptor-side IL17RA and kinase-side TYK2 mechanisms when downstream drug pages expose them, rather than staying ligand-only", |
| "Ustekinumab must be removed only when target interpretation shows IL12 + IL23A rather than the IL-17/IL-23-axis criterion required here", |
| "systemic-use, Japanese 3999, and PMDA-date filtering must be applied after each candidate-space expansion rather than attached to the earlier ligand-only state" |
| ], |
| "freeze": { |
| "historical_window": "Japanese plaque-psoriasis systemic drugs approved on or before 2024-12-31; current KEGG drug-entry annotations supply target branches and Japan approval dates" |
| }, |
| "answer_type": "multi-row ordered table" |
| }, |
| "rubric": { |
| "inclusion_conditions": [ |
| "只保留截至 2024-12-31 前已在日本获批、用于斑块状银屑病的系统用药中，真正作用于 IL-17/IL-23 信号轴的活性成分。", |
| "候选集合必须覆盖 ligand side、receptor side 和 TYK2 kinase side，而不是只看 interleukin ligand 一侧。", |
| "最终条目按日本首次批准日期升序排列；如同日则按 DRUG_ID 升序。" |
| ], |
| "exclusion_conditions": [ |
| "排除外用药、非系统用药或不在指定历史冻结窗口内的条目。", |
| "排除 Ustekinumab 这类实际暴露为 IL12 + IL23A、但不满足本题 IL-17/IL-23 轴口径的条目。", |
| "排除因为只看 ligand side 而漏掉 Brodalumab 或 Deucravacitinib 的结果。" |
| ], |
| "normalization": { |
| "field_separator": "|", |
| "record_separator": "\n", |
| "header_row": "omit the header row; emit data rows only", |
| "schema": [ |
| "DRUG_ID", |
| "Name", |
| "ATC", |
| "Target_branch", |
| "PMDA_date" |
| ], |
| "PMDA_date": "use the canonical KEGG-style date format YYYY/M/D with no zero-padding requirement beyond the source value", |
| "Target_branch": "emit the most specific target branch visible in the source path; when multiple parallel branches survive, join them with `/`", |
| "sorting_or_selection": { |
| "primary": "PMDA_date ascending", |
| "secondary": "DRUG_ID ascending" |
| } |
| } |
| } |
| } |
|
|
